Genomics is a precision medicine company accelerating target discovery and clinical development through large-scale genomic insights powered by AI/ML-driven analysis. We were formed in 2014 by four ground-breaking statistical and human geneticists at the University of Oxford.
Today, we are collaborating with some of the world’s leading innovators in drug development, enabling them to leverage genomics to de-risk decision making, identify and validate targets, improve trial success rates, and reduce trial time-to-completion. Our cutting-edge solutions support the advancement of groundbreaking therapies, enabling our partners to accelerate the discovery and commercialisation of next-generation treatments.